Business Context and Reporting Period
This Form 8-K was filed by Trovagene, Inc. (not Cardiff Oncology, Inc.) on February 12, 2019. The report details the results of a Special Meeting of Stockholders held on the same date to vote on corporate governance matters.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on the outcome of a stockholder vote and does not contain financial performance data.
Material Changes
The primary material event reported is the stockholder approval of an amendment to the Company's Certificate of Incorporation. This amendment authorizes a reverse stock split of the Company's common stock at a ratio between 1-for-2 and 1-for-6, to be determined by the Board of Directors and effected, if at all, on or before January 15, 2020.
Voting Results and Governance
- Quorum: 13,430,016 shares of common stock were represented at the meeting.
- Proposal 1 (Reverse Stock Split):
- For: 11,586,099 votes
- Against: 1,728,001 votes
- Abstain: 115,916 votes
The proposal was approved by the stockholders.
Investor Verification Checklist
- Verify the specific reverse stock split ratio selected by the Board of Directors, as the vote only authorized a range (1-for-2 to 1-for-6).
- Confirm the effective date of the reverse stock split, noting the deadline of January 15, 2020.
- Review the Definitive Proxy Statement filed on December 18, 2018, for detailed rationale and risks associated with the reverse split.
- Clarify the discrepancy between the requested company name (Cardiff Oncology, Inc.) and the actual registrant in the filing (Trovagene, Inc.).